Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tempus AI, Inc. Class A Common Stock (TEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: TEM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $73.45
1 Year Target Price $73.45
| 4 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.29% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.12B USD | Price to earnings Ratio 40.48 | 1Y Target Price 73.45 |
Price to earnings Ratio 40.48 | 1Y Target Price 73.45 | ||
Volume (30-day avg) 12 | Beta - | 52 Weeks Range 31.36 - 91.45 | Updated Date 09/17/2025 |
52 Weeks Range 31.36 - 91.45 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.98% | Operating Margin (TTM) -19% |
Management Effectiveness
Return on Assets (TTM) -11.51% | Return on Equity (TTM) -97.95% |
Valuation
Trailing PE 40.48 | Forward PE - | Enterprise Value 15683192647 | Price to Sales(TTM) 15.88 |
Enterprise Value 15683192647 | Price to Sales(TTM) 15.88 | ||
Enterprise Value to Revenue 16.47 | Enterprise Value to EBITDA - | Shares Outstanding 168683769 | Shares Floating 104425898 |
Shares Outstanding 168683769 | Shares Floating 104425898 | ||
Percent Insiders 41.83 | Percent Institutions 44.1 |
Upturn AI SWOT
Tempus AI, Inc. Class A Common Stock
Company Overview
History and Background
Tempus AI, Inc. is a technology company focused on precision medicine through the use of artificial intelligence. Founded in 2015, Tempus aims to personalize healthcare by analyzing molecular and clinical data.
Core Business Areas
- Genomics Sequencing: Provides comprehensive genomic sequencing services to identify genetic variations associated with disease.
- Data Analytics and AI: Uses AI to analyze large datasets of molecular and clinical information to identify patterns and insights.
- Clinical Trial Matching: Connects patients with relevant clinical trials based on their genomic and clinical profile.
- Real-World Data (RWD) Solutions: Offers access to curated, real-world data to support research and development of new therapies.
Leadership and Structure
Eric Lefkofsky is the Founder and CEO. The company has a hierarchical structure with distinct teams focused on technology, research, and commercialization.
Top Products and Market Share
Key Offerings
- xT (Genomic Sequencing): A comprehensive genomic sequencing test for cancer patients. Offers insights into actionable mutations for treatment decisions. Market share data is still evolving but Tempus is a significant player. Competitors include Foundation Medicine (owned by Roche), Guardant Health, and Caris Life Sciences.
- TIME (Data Platform): A data platform that integrates genomic, clinical, and imaging data. Used by researchers and pharmaceutical companies for drug discovery and development. Competitors include Flatiron Health (owned by Roche), ConcertAI, and Komodo Health.
Market Dynamics
Industry Overview
The precision medicine industry is experiencing rapid growth, driven by advances in genomics, data analytics, and AI. There's increasing demand for personalized treatments and data-driven drug development.
Positioning
Tempus is positioned as a leader in the precision medicine space, leveraging its integrated platform of genomic sequencing, data analytics, and AI to personalize healthcare. Its competitive advantage lies in its comprehensive data platform and AI capabilities.
Total Addressable Market (TAM)
The precision medicine market is estimated to be hundreds of billions of dollars. Tempus is positioned to capture a significant portion of this TAM through its comprehensive platform and partnerships with healthcare providers and pharmaceutical companies.
Upturn SWOT Analysis
Strengths
- Integrated platform combining genomics, data analytics, and AI
- Strong partnerships with leading cancer centers and pharmaceutical companies
- Proprietary data assets
- Experienced leadership team
- Advanced technology
Weaknesses
- High operating expenses
- Reliance on partnerships
- Complex regulatory environment
- Data privacy concerns
- Relatively young company, not yet profitable
Opportunities
- Expanding into new disease areas beyond cancer
- Developing new AI-powered diagnostics and therapeutics
- Scaling its clinical trial matching program
- Increasing adoption of precision medicine by healthcare providers
- International expansion
Threats
- Increasing competition from established players and startups
- Changes in reimbursement policies
- Data security breaches
- Ethical concerns related to AI in healthcare
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- FMI
- GH
- ROSY
- ILLU
Competitive Landscape
Tempus AI competes with established players in genomics and data analytics. It's advantageous because of its integrated platform but disadvantaged due to its high operating costs and recent IPO.
Major Acquisitions
Highmark Interactive
- Year: 2023
- Acquisition Price (USD millions): 45
- Strategic Rationale: Enhance Tempus AI's data analytics and digital pathology capabilities, enabling more comprehensive patient profiling and diagnostic support.
Growth Trajectory and Initiatives
Historical Growth: Discuss Tempus AI, Inc.'s growth trends over the past years.
Future Projections: Provide projections for Tempus AI, Inc.'s future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Tempus AI, Inc.
Summary
Tempus AI is a rapidly growing precision medicine company with a strong technological foundation in genomics and AI. Its integrated platform offers a competitive advantage but faces challenges related to profitability and regulatory complexities. Strategic partnerships and expansion into new disease areas are crucial for its future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempus AI, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2024-06-14 | Co-Founder, CEO, President & Chairman Mr. Eric P. Lefkofsky J.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2400 | Website https://www.tempus.com |
Full time employees 2400 | Website https://www.tempus.com | ||
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology, as well as strategic collaboration with Personalis, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.